ENE. S. Nokhrina

E. S. Nokhrina

*This is an algorithmically generated author record based on publicly available information.

E. S. Nokhrina has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pediatric B-lineage acute lymphoblastic leukemia with CRLF2 rearrangements. Own experience in molecular genetic diagnostics and patient monitoring

    by I.S. Kotov, G.A. Tsaur, E.A. Chetverikova, E.S. Nokhrina, T.A. Mukhacheva, A.I. Ponomarev, Zh.V. Permikin, T.Y. Verzhbitskaya, O.R. Arakaev, A.A. Vlasova, et al.

    B-lineage acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements is characterized by high genetic heterogeneity and can be accompanied with mutations in the JAK-STAT signaling pathway, intrachromosomal amplification of chromosome 21 (iAMP21), dic (9;20), as well as IKZF1 deletions and has an unfavorable outome. Purpose. To characterize clinical, immunological and molecular genetic features of children with B-lineage ALL with CRLF2 rearrangements. Materials and methods. The study included 958 children aged 1-18 years with primarily diagnosed B-lineage ALL. Among them, a search for CRLF2 rearrangements was carried out using the fluorescence in situ hybridization, and the spectrum of genetic aberrations was analyzed using multiplex ligase-dependent probe amplification (MLPA) and targeted next-generation sequencing of RNA. Results. CRLF2 rearrangements were detected in 58 (6.1%) patients, including 42 with P2RY8::CRLF2 (72.4%) and 16 with IGH::CRLF2 (27.6%). Patients with IGH::CRLF2 fusion gene were significantly older, more often had an initial WBC ≥50×109/L and were significantly more often classified as high-risk according to the criteria of the US National Cancer Institute, however no significant differences in survival and cumulative incidence of relapse between these groups were found. JAK1/2 mutations were detected in 14.0% of CRLF2-rearranged patients, RAS family gene mutations in 23.3% and PAX5 alterations (both point mutations and fusion genes) in 18.6%. Seventeen patients (37.7%) with IKZF1 deletions were identified, while 10 of them (22.2%) had the IKZF1plus profile. With a median follow-up time of 5.3 years, the event-free survival of patients with ALL and CRLF2 rearrangements was 0.49 (standard error (SE) 0.22) and the cumulative incidence of relapse was 0.46 (SE 0.12). The most unfavorable outcome was observed in patients with IKZF1plus profile. Of note, the persistence of minimal residual disease at the end of remission induction did not have a statistically significant impact on the prognosis of patients with ALL and CRLF2 rearrangements. Conclusions. In our cohort of pediatric patients with B-lineage ALL the incidence of CRLF2 rearrangements was 6.1%. These patients showed significant genetic heterogeneity and unfavorable outcome.

  • Open Access

    Additional genetic aberrations detected by fluorescence in situ hybridization in children with acute lymphoblastic leukemia and the t(12;21)(p13;q22)/ETV6::RUNX1 translocation: an association with initial clinical and laboratory findings and response to therapy

    by I. S. Kotov, G. A. Tsaur, E. S. Nokhrina, A. V. Ryakshina, Yu. V. Olshanskaya, Zh. V. Permikin, T. Yu. Verzhbitskaya, T. O. Riger, A. I. Ponomarev, O. V. Streneva, et al.

    Translocation t(12;21)(p13;q22)/ETV6::RUNX1 is among the most common genetic aberrations in pediatric B-cell precursor acute lymphoblastic leukekian (BCP-ALL). This translocation is often combined with ETV6 and/or RUNX1 copy number variations. Fluorescence in situ hybridization (FISH) technique, which is widely used to reveal the presence of t(12;21)(p13;q22), also allows the detection of these additional genetic aberrations (FISH patterns). The aim of this study was to provide detailed characteristics of FISH patterns in patients with BCP-ALL and the t(12;21)(p13;q22)/ETV6::RUNX1 translocation. In our study we enrolled 241 patients with t(12;21)-positive ALL who had undergone testing with a dual-color double-fusion FISH assay between 2008 and 2023. This study was approved by the Independent Ethics Committee and the Academic Council of the Research Institute of Medical Cell Technologies (Ekaterinburg). A single FISH pattern (monoclonal cases) was identified in 200 patients (83.0%), 2 or more patterns (polyclonal cases) were detected in 41 (17.0%) patients. The majority of polyclonal cases (n = 39; 95.1%) exhibited 2 patterns. The most common secondary genetic alteration was ETV6 deletion (n = 105; 43.5%). Less common aberrations included an additional copy of RUNX1 (n = 97; 40.2%), a combination of ETV6 deletion and an additional copy of RUNX1 (n = 27; 11.2%), and an additional copy of ETV6 (n = 5; 2.0%). The number of the patients with one FISH pattern that did not contain any additional genetic aberrations as a result of a reciprocal translocation (2F1G1R) was relatively small (n = 35; 17.5%). We identified 5 prognostically unfavorable FISH patterns associated with a high risk of relapse. These included cases with simultaneous presence of ETV6 and RUNX1 additional copies (pattern 2F2G2R), isolated additional copies of RUNX1 (pattern 2F2R-3F2R) or ETV6 (pattern 1F1G2R-2F2G4R), a partial deletion of ETV6 (pattern 2F1Gdim1R) and a non-reciprocal translocation of t(12;21) (pattern 1F1R-1F1G1R). Grouping these unfavorable prognostic FISH patterns together made it possible to predict 6 (46%) out of 13 relapses that occurred in the patients during the study period. It is important to highlight that the number of the patients with unfavorable FISH patterns and initial leukocytosis of 30 × 109 leukocytes/L did not differ significantly from the rest of the group. Another important observation was that the patients with prognostically unfavorable FISH patterns responded well to induction therapy, as assessed both by cytological examination of blood and bone marrow smears on days 8, 15, and 36 of therapy and by MRD response at the end of induction therapy according to the ALL-MB 2015 protocol. A comparison of FISH patterns detected at initial diagnosis and at relapse showed that only 6 (50%) out of 12 cases who had undergone FISH testing at both time points remained stable. In conclusion, BCP-ALL with the translocation t(12;21)(p13;q22)/ETV6::RUNX1 was characterized by a vast variety of secondary genetic aberrations detected by FISH, the most prevalent of which was ETV6 deletion. A group of unfavorable FISH patterns identified in our study warrants further investigation in a larger cohort of ALL patients for their possible re-stratification so that they could receive more intensive treatment.

  • Application of CD27 AND CD44 expression for prediction of ETV6::RUNX1 fusion gene presence in pediatric B-CELL precursor acute lymphoblastic leukemia

    by Zh.V. Permikin, G.A. Tsaur, T.YU. Verzhbitskaya, T.O. Riger, E.S. Nokhrina, O.M. Plekhanova, L.I. Saveliev, O.P. Kovtun, S.V. Tsvirenko, L.G. Fechina, et al.

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить возможность прогнозирования наличия транслокации t(12;21)(p13;q22)/ETV6::RUNX1 методом проточной цитометрии с использованием антигенов CD27 и CD44 у детей с острым лимфобластным лейкозом из B-линейных предшественников (ВП-ОЛЛ). МЕТОДЫ ИССЛЕДОВАНИЯ В исследование вошло 437 случаев ВП-ОЛЛ у детей в возрасте от 1 до 18 лет. Процентное количество CD27 и CD44 позитивных опухолевых клеток, а также средняя интенсивность флуоресценции (MFI) были сопоставлены с результатами молекулярно-генетических методов исследования. Оптимизация порогового уровня для определения позитивной экспрессии антигенов CD27 и CD44 была проведена с помощью ROC-анализа. РЕЗУЛЬТАТЫ Было доказано, что транслокация t(12;21)(p13;q22)/ETV6::RUNX1 ассоциирована с сочетанием позитивной экспрессии CD27 и сниженной, либо отсутствующей экспрессией CD44. Тем не менее, оптимальными пороговыми уровнями для определения позитивной экспрессии CD27 и CD44 в процентах оказались 80,7 и 86,1% соответственно. Использование отношения MFI CD27 к MFI CD44 показало наиболее высокий параметр диагностического отношения шансов — 953,1. ЗАКЛЮЧЕНИЕ Использование сочетания антигенов CD27 и CD44 позволило с высокой диагностической эффективностью предсказывать наличие t(12;21)(p13;q22)/ETV6::RUNX1 при ВП-ОЛЛ у детей методом проточной цитометрии.